GENE ONLINE|News &
Opinion
Blog

2021-10-13| LicensingSpecial

Takeda Inks $3.6 Billion Deal with Poseida to Advance Non-Viral Gene Therapies and Overcome Safety Issues

by Rajaneesh K. Gopinath
Share To
Takeda seems to have embarked on a deal-making binge in the past few days. Just last week, the Japanese pharma giant signed a billion-dollar strategic partnership with Selecta Biosciences to develop targeted gene therapies for lysosomal storage disorders. Yesterday, it emulated that with another massive deal!

On October 11th, Takeda announced a $3.6 billion gene therapy pact with San Diego-based Poseida Therapeutics. The exclusive license agreement aims to utilize Poseida's proprietary technologies for the research and development of up to eight gene therapies.

Speaking to GeneOnline, Eric Ostertag, CEO of Poseida Therapeutics, said both companies are philosophically very aligned in terms of patient care and in trying to get innovative treatments to patients with unmet medical needs, primarily pediatric patients.

GO Prime with only $1.49 now

LATEST
Recounting 25 Years of Genetic and Human Diversity Discovery With deCODE Founder Kari Stefansson
2022-05-26
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia
2022-05-25
These Companies Are Harnessing Oncolytic Viruses to Target Cancer
2022-05-25
Lonza Signs CDMO Deal to Break Into Israeli Market
2022-05-25
EU Expands Merck’s Keytruda Use on Breast Cancer
2022-05-25
Travecta Therapeutics Announces In-Person Presentation at 2022 BIO International Convention
2022-05-24
Global Race to Track and Contain Monkeypox Outbreak
2022-05-24
EVENT
2022-06-03
ASCO Annual Meeting
Online and on-side
2022-06-07
Digital RESI June
Online
2022-06-09
Medhospafrica
Africa
2022-06-13
BIO International Convention
San Diego, CA
2022-12-14
BIOHK2022
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!